Hookipa Pharma (NASDAQ:HOOK) Rating Increased to Buy at Zacks Investment Research

Hookipa Pharma (NASDAQ:HOOK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. The brokerage currently has a $7.75 price target on the stock. Zacks Investment Research‘s target price points to a potential upside of 10.87% from the stock’s previous close.

According to Zacks, “HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company. It is engaged in developing a class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform which is designed to reprogram the body’s immune system. HOOKIPA Pharma Inc. is based in New York, United States. “

HOOK has been the subject of a number of other research reports. Svb Leerink initiated coverage on Hookipa Pharma in a report on Monday, May 13th. They issued an “outperform” rating and a $20.00 target price for the company. Royal Bank of Canada restated a “buy” rating and issued a $23.00 target price on shares of Hookipa Pharma in a report on Wednesday. Bank of America began coverage on shares of Hookipa Pharma in a research note on Monday, May 13th. They issued a “buy” rating and a $17.00 price target on the stock. Finally, Leerink Swann began coverage on shares of Hookipa Pharma in a research note on Monday, May 13th. They issued an “outperform” rating and a $20.00 price target on the stock. Five analysts have rated the stock with a buy rating, Hookipa Pharma currently has an average rating of “Buy” and a consensus target price of $17.55.

Shares of HOOK traded down $0.01 during mid-day trading on Thursday, reaching $6.99. The company’s stock had a trading volume of 17,294 shares, compared to its average volume of 113,503. The company has a fifty day moving average price of $6.98. Hookipa Pharma has a 1 year low of $6.06 and a 1 year high of $14.76.

Hookipa Pharma (NASDAQ:HOOK) last released its earnings results on Monday, May 20th. The company reported ($9.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($8.85). The firm had revenue of $2.24 million during the quarter, compared to the consensus estimate of $0.50 million. On average, equities analysts expect that Hookipa Pharma will post -2.14 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of HOOK. Tower Research Capital LLC TRC acquired a new position in Hookipa Pharma during the second quarter worth $40,000. Northern Trust Corp acquired a new position in Hookipa Pharma during the second quarter worth $72,000. Morgan Stanley acquired a new position in Hookipa Pharma during the second quarter worth $99,000. Vanguard Group Inc. acquired a new position in Hookipa Pharma during the second quarter worth $538,000. Finally, BlackRock Inc. acquired a new position in Hookipa Pharma during the second quarter worth $737,000.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

See Also: Penny Stocks, What You Need To Know

Get a free copy of the Zacks research report on Hookipa Pharma (HOOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit